Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Norgine and Takeda Pharmaceutical Company Limited has announced that the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application (NDA) of OBLEAN Tablets 120mg for the treatment of obesity with complications.
OBLEAN is a lipase inhibitor discovered by UK-based Alizyme Therapeutics Limited. Norgine acquired all rights to the product from Alizyme in October 2009. In 2003 Takeda acquired the rights for development and commercialisation for Japan.
OBLEAN inhibits the activity of lipase, a lipolytic enzyme, secreted by the digestive tract and pancreas, and blocks the absorption of fat from the gut, resulting in not only reduced body weight, but also reduced visceral fat and improved parameters related to lifestyle diseases. OBLEAN is the first therapy that controls lipid absorption approved in Japan for the treatment of obesity with complications.
The NDA submission is based on the results of three phase 3 clinical trials in obese patients with type 2 diabetes and dyslipidemia: a 52-week placebo-controlled, double-blind study to evaluate the efficacy and safety, and two open-label studies to evaluate safety, 24-week and 52-week respectively. The results of the 52-week placebo-controlled, double-blind study demonstrate that OBLEAN 120mg three times daily is superior to placebo in the primary endpoint, with a mean reduction in body weight from baseline of -2.776% with OBLEAN versus -1.103% with placebo (p=0.0020). Greater reductions in HbA1c and low-density lipoprotein cholesterol were also observed in patients treated with OBLEAN, compared to placebo. In all these three studies, OBLEAN showed a good safety profile and was well tolerated. [1, 2, 3]
In filing for this approval, Takeda utilised the Preliminary Assessment of the Pharmaceuticals and Medical Devices Agency (PMDA).*
Paul Pay, VP Corporate and Business Development at Norgine said; "Being overweight or obese is a major risk factor in the development of many chronic diseases and we are pleased that Takeda has obtained manufacturing and marketing approval by the regulatory authorities in Japan."
"Obesity is an increasingly important issue in Japan with limited treatment options" said Nancy Joseph-Ridge M.D., General Manager of Takeda's Pharmaceutical Development Division. "The approval of OBLEAN, with its novel mechanism of action, provides options for this unmet medical need to patients with obesity, with complications of both type 2 diabetes and dyslipidaemia in Japan."
Type 2 diabetes develops when the body can't produce enough insulin, or when the insulin that is produced doesn't work properly. If untreated, it can cause very serious health problems.
HbA1c is a term often used in relation to diabetes. HbA1c occurs when haemoglobin joins with glucose in the blood. Haemoglobin molecules make up the red blood cells in the blood stream. When glucose sticks to these molecules it forms a glycosylated haemoglobin molecule, also known as A1c and HbA1c. The more glucose found in the blood the more glycated haemoglobin (HbA1c) will be present.
LDL collects in the walls of blood vessels, causing the blockages of atherosclerosis. Higher LDL levels put people at greater risk for a heart attack from a sudden blood clot in an artery narrowed by atherosclerosis.
Usually, for adults, a dose of 120 mg is orally administered, three times a day, immediately after each meal.
Obesity (limited to patients with both type 2 diabetes mellitus and dyslipidemia, and with a BMI≥25 kg/m2 in spite of dietary treatment and/or exercise therapy)
* A type of PMDA consultation that is conducted at the development stage before NDA submission based on the available quality, non-clinical and clinical data and that is primarily intended to identify the issues anticipated during the NDA review as much as possible.
 A Phase 3, Multicentre, Randomized, Stratified, Placebo-controlled, Double-blind, Parallel-group Study to Investigate the Efficacy and Safety of ATL-962 in Obese Patients with Type 2 Diabetes and Dyslipidemia. Protocol No. ATL-962/CCT-002. Takeda Pharmaceutical Company Limited, Osaka, Japan
 A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of ATL-962 in Obese Patients with Type 2 Diabetes and Dyslipidemia. Protocol No. ATL-962/OCT-001. Takeda Pharmaceutical Company Limited, Osaka, Japan
 A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Long-term Treatment with ATL-962 in Obese Patients with Type 2 Diabetes Mellitus and Dyslipidemia. Protocol No. ATL-962/OCT-002. Takeda Pharmaceutical Company Limited, Osaka, Japan
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Regulatory Affairs / Drug Approvals category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Norgine. "Norgine and Takeda announce the new drug application approval of Oblean (cetilistat) tablets 120mg in Japan." Medical News Today. MediLexicon, Intl., 24 Sep. 2013. Web.
13 Dec. 2013. <http://www.medicalnewstoday.com/releases/266459>
Norgine. (2013, September 24). "Norgine and Takeda announce the new drug application approval of Oblean (cetilistat) tablets 120mg in Japan." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/266459.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.